The RACTAC phase II clinical study was designed to investigate whether adding CPZ to the standard adjuvant TMZ in the Stupp protocol could improve therapeutic efficacy in patients with GBM with an unmethylated MGMT gene promoter. Here, MGMT is linked to glioblastoma.